Inventiva Pauses Late-Stage NASH Trial, Keeps Field Open for Madrigal

French biotech Inventiva on Thursday announced during its 2023 earnings report that it was voluntarily suspending the screening and enrollment of patients in the Phase III NATiV3 study for its investigational oral drug lanifibranor in non-alcoholic steatohepatitis.